Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review

Cancer therapies targeting human epidermal growth factor receptor 2 (HER2) have been attracting increasing attention worldwide, especially in lung adenocarcinoma. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric c...

Full description

Bibliographic Details
Main Authors: Xiangjun Qi, Jiayun Guo, Xiaoqi Zhou, Lingling Sun, Jietao Lin, Zijing Huang, Hanrui Chen, Lizhu Lin
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Heliyon
Subjects:
Disitamab vedotin
Antibody-drug conjugate
Lung adenocarcinoma
Human epidermal growth factor receptor 2
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844022018692

Similar Items

Similar Items